home

 

Providing Targeted Cancer Diagnostics

News

UCL-AD Validates New ALK IHC Assay for NSCLC

UCL-AD is in the process of validating the new Roche Tissue Diagnostics ALK IHC protein assay for use in Non-Small Cell Lung Cancer (NSCLC) for patients whom Crizotinib (Xalkori, Pfizer) treatment is being considered.

This amplified assay, which is used to detect low level expression of the ALK protein, generated as a result of the ALK gene re-arrangement, will enable NSCLC patients to obtain an accurate, rapid and cost effective, same day ALK screen.

To view examples of ALK positive IHC cases (1 -8) stained at UCL-AD please click on the dynamic digital pathology links below to view the digital slides.

Case 8 is a newly developed ALK positive cell line which is to be used as part of a new ALK IHC EQA scheme from UKNEQAS ICC & ISH.

CASE 1

 

CASE 2

 

CASE 3

 

CASE 4

 

CASE 5

 

CASE 6

 

CASE 7

 

CASE 8

 


ALK FISH Positive Case taken from the European Society of Pathology (ESP)
ALK EQA Tissue Microarray.